10 results about "Guanine Nucleotides" patented technology

The application discloses a method for purifying and chromatographing and mass spectrometrically identifying deoxyguanosine or 3-hydroxybenzoic acid and application. After metabolites are extracted by a methanol method, UPLC-MS / MS-ultra high performance liquid chromatography and ABSCIEX QTRAP 5500 triple quadrupole tandem linear ion trap mass spectrometry are used to distinguish the metabolites by using liquid chromatography and mass spectrometry. The MS technology provides the ability to detect and quantify a large number of metabolites. The method optimizes the purification and mass spectrometric identification of the progeria markers in blood, identifies the structures of the differential markers deoxyguanosine and 3-hydroxybenzoic acid in blood by using the mass spectrometric method, and distinguishes the difficult-to-distinguish differential markers. The method for purifying and mass spectrometrically identifying the progeria differential markers in blood is simple and easy to operate, has small experimental dosage, good stability, is fast and accurate, and can make up for the deficiency in searching for the blood differential markers.

Disclosed herein are compositions comprising an oligonucleotide that targets SOS Ras / Rho guanine nucleotide exchange factor 2 (SOS2). The oligonucleotide may include a small interfering RNA (siRNA) or an antisense oligonucleotide (ASO). Also provided herein are methods of treating conditions associated with SOS2 mutations that include providing an oligonucleotide that targets SOS2 to a subject.

The invention discloses an immobilized nucleoside enzyme mutant and application thereof. The immobilized nucleoside enzyme mutant is prepared by covalently immobilizing a nucleoside enzyme mutant G178D / A202K on aminated magnetic Fe3O4 nanoparticles. The catalyst is applied to a hydrolysis reaction of guanine nucleotide (GMP), efficient catalysis is carried out in a water phase at 60-70 DEG C, the catalyst can be rapidly separated and recovered through an external magnetic field after the reaction, and then high-purity guanine is obtained through solid-liquid separation. The immobilized enzyme can be repeatedly used for more than or equal to 8 times, still keeps more than or equal to 80% of activity, remarkably improves the industrial efficiency of guanine preparation, and has the advantages of green process, simplicity and convenience in operation, low cost, easiness in industrialization and the like.

The present disclosure provides methods of treating subjects having glaucoma or elevated intraocular pressure (IOP), methods of identifying subjects having an increased risk of developing glaucoma or developing elevated IOP, methods of detecting human Rho Guanine Nucleotide Exchange Factor 12 (ARHGEF12) variant nucleic acid molecules and variant polypeptides, and ARHGEF12 variant nucleic acid molecules and variant polypeptides.

The present disclosure provides methods of treating subjects having glaucoma or elevated intraocular pressure (IOP), methods of identifying subjects having an increased risk of developing glaucoma or developing elevated IOP, methods of detecting human Rho Guanine Nucleotide Exchange Factor 12 (ARHGEF12) variant nucleic acid molecules and variant polypeptides, and ARHGEF12 variant nucleic acid molecules and variant polypeptides.

Polypeptide cosmetic compositions may be useful for addressing skin conditions. Such skin conditions include loss of firmness, lines and wrinkles, and other age-related skin changes associated with the general degradation of the skin dermis, which are often characterized by collagen loss and structural disorganization. Cosmetic compositions may comprise a polypeptide, a first polypeptide activator comprising a guanine nucleotide, and a second polypeptide activator comprising succinic acid. Preferably, the polypeptide has about 5 amino acid residues or less, and more preferably, the polypeptide comprises a tripeptide having an amino acid sequence of Ser-Thr-Pro-NH2. Preferred polypeptides may promote stimulation of collagen production in skin cells to which the cosmetic compositions are applied.

The invention discloses a purification and chromatography-mass spectrometry identification method of deoxyguanine mononucleotide or / 3-hydroxybenzoic acid and an application of the deoxyguanine mononucleotide or / 3-hydroxybenzoic acid. After metabolites are extracted by a methanol method, UPLC-MS / MS-ultra-high performance liquid chromatography and ABSCIEX QTRAP 5500 triple quadrupole tandem linear ion trap mass spectrometry are used, and the metabolites are distinguished by liquid chromatography and mass spectrometry. MS technology provides the ability to detect and quantify large quantities of metabolites. According to the method disclosed by the invention, purification and mass spectrum identification of the progeria marker in the blood are optimized, and the structures of the differential markers, namely deoxysingle guanine nucleotide and 3-hydroxybenzoic acid, in the blood are identified by utilizing a mass spectrum method, so that the differential markers which are difficult to distinguish are distinguished. The method for purification and mass spectrum identification of the difference markers of the premature senility in the blood is simple, convenient and easy to implement, small in experimental dosage, good in stability, rapid and accurate, and can make up for the defect of finding the difference markers of the blood at present.

Polypeptide cosmetic compositions may be useful for addressing skin conditions. Such skin conditions include loss of firmness, lines and wrinkles, and other age-related skin changes associated with the general degradation of the skin dermis, which are often characterized by collagen loss and structural disorganization. Cosmetic compositions may comprise a polypeptide, a first polypeptide activator comprising a guanine nucleotide, and a second polypeptide activator comprising succinic acid. Preferably, the polypeptide has about 5 amino acid residues or less, and more preferably, the polypeptide comprises a tripeptide having an amino acid sequence of Ser-Thr-Pro-NH2. Preferred polypeptides may promote stimulation of collagen production in skin cells to which the cosmetic compositions are applied.

The invention described herein provides eIF2B agonist (e.g., COMPOUND 1 ) and uses thereof for treatment of diseases, especially neurodegenerative diseases, including vanishing white matter (VWM), Huntington's disease (HD), Charcot Marie Tooth syndrome (CMT), and Amyotropic Lateral Sclerosis (ALS).

The invention provides an antibody or an antigen binding fragment thereof, a preparation method and application. The antibody or the antigen binding fragment thereof targets reversible terminating guanine nucleotide, and comprises a heavy chain complementarity determining region HCDR, and the HCDR comprises at least one selected from SEQ ID NO: 1-3 or an amino acid sequence having at least 80% homology with the HCDR. The antibody or the antigen binding fragment thereof is applied to a sequencing scene, and compared with an existing antibody, the antibody or the antigen binding fragment thereof is low in preparation cost, higher in affinity to reversible terminating nucleotide, higher in specificity and capable of effectively reducing reversible terminator crosstalk and obviously improving sequencing accuracy.